Kailera Therapeutics (NASDAQ:KLRA) Reaches New 52-Week Low – Here’s What Happened

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) hit a new 52-week low on Tuesday . The company traded as low as $16.75 and last traded at $16.76, with a volume of 311398 shares traded. The stock had previously closed at $17.48.

Analysts Set New Price Targets

A number of brokerages have issued reports on KLRA. William Blair assumed coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. began coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “overweight” rating and a $30.00 price target on the stock. Evercore assumed coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating for the company. TD Cowen began coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 price objective for the company. Finally, Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $42.75.

Kailera Therapeutics Stock Down 4.2%

The stock has a fifty day moving average price of $20.43. The firm has a market cap of $2.17 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last posted its quarterly earnings results on Tuesday, May 26th. The company reported ($3,650.00) earnings per share (EPS) for the quarter.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.